読み込み中
NASDAQConsumer CyclicalAuto - Parts
最新データ
$8.30
$0.00 · 0.00%
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
前日終値
$8.30
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日中レンジ
現在 $8.30
52週レンジ
現在 $8.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
51
まちまち
リスク
57
やや高いリスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
日中レンジ
現在 $8.30
52週レンジ
現在 $8.30
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6202 USD | — | — | — | — |
| 売上原価 | 6318 USD | — | — | — | — |
| 粗利益 | −116 USD | — | — | — | — |
| 研究開発 | 92.39万 USD | 14.44万 USD | 7.21万 USD | — | — |
| 販売・一般管理 | 1842.73万 USD | 106.65万 USD | 134万 USD | 97.63万 USD | 2.78万 USD |
| 営業費用 | 1935.12万 USD | 121.09万 USD | 134万 USD | 97.63万 USD | 2.55万 USD |
| 受取利息 | — | 54.87万 USD | 581.3万 USD | 431.66万 USD | — |
| 支払利息 | 853.13万 USD | 9.8万 USD | 8966 USD | — | — |
| 減価償却費と償却費 | 801.94万 USD | — | 134.02万 USD | — | 2.78万 USD |
| 営業利益 | −1935.13万 USD | −121.09万 USD | −134万 USD | −97.63万 USD | −2.55万 USD |
| 純利益 | −2448.08万 USD | −130.99万 USD | 446.4万 USD | 334.02万 USD | −2.55万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年5月11日 | 1:30 | — | — |
株式分割 | 2026年1月16日 | 1:40 | — | — |
発効済み 2026年5月11日
1:30
発効済み 2026年1月16日
1:40
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
